OSI Will Not Pursue Additional Studies Of Aptosyn With Taxotere For Non-Small Cell Lung Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
A Phase III trial inherited through the Cell Pathways acquisition failed to demonstrate a benefit in overall survival with Aptosyn/Taxotere compared to Taxotere plus placebo. OSI says it remains committed to developing pro-apoptotic anti-cancer agents.